Late-stage clinical trial failures in Duchenne muscular dystrophy continue to plague this therapeutic sector, with Roche discontinuing its RG6206 (RO7239361) program. The decision emerged on 6 November in communications Roche addressed to the patient community, and quickly spread to the internet.
Roche Discontinues Duchenne Hope At Interim Analysis
Anti-Myostatin Approach Disappoints Again
Roche is to discontinue its RG6206 clinical development program in Duchenne muscular dystrophy after an interim analysis of the Phase II/III SPITFIRE study indicates the compound would be “highly unlikely” to show a clinical benefit.
More from Rare Diseases
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.